Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences
AssigneeDepartment Central De Fractionment De La Croix-Rouge Scrl
InventorsRuth Laub, Mario Giambattista
Life of this patent
Estimating the term…
Abstract
The present invention is related to the antigenic polypeptide sequence of Factor VIII.
Claims8
An isolated or purified antigenic fragment of a human factor VIII polypeptide, such fragment comprising an epitope of factor VIII, wherein said epitope is the epitope isoleucine 2262 to glutamine 2270 inclusive, defined by the following sequence:
- Ile Ser Ser Ser Gln Asp Gly His Gln of SEQ ID NO:
- 30.
A pharmaceutical composition comprising an adequate pharmaceutical carrier and the polypeptide of claim 2.
An isolated or purified antigenic fragment of a human factor VIII polypeptide, such fragment comprising at least seven amino acids of a human factor VIII C domain positioned between amino acids 2020 and 2332 of SEQ ID NO:
- 49.
An isolated or purified antigenic fragment of a human Factor VIII polypeptide, such fragment comprising at least seven amino acids of the human Factor VIII C domain fragment, selected from the group consisting of the following fragments of factor VIII polypeptide of SEQ ID NO:
- 49, wherein said Factor VIII C domain is positioned between amino acids 2020 and 2332 of SEQ ID NO:
- 49:
- a) a sequence starting from glycine 2242 to tyrosine 2332 inclusive;
- b) a sequence starting from glycine 2242 to tyrosine 2305 inclusive;
- c) the sequence of (b), wherein one or more amino acids of the terminal peptide Thr-Arg-Tyr are deleted;
- d) a sequence starting from isoleucine 2262 to serine 2289 inclusive;
- e) a sequence starting from leucine 2273 to tyrosine 2332 inclusive;
- f) a sequence starting from leucine 2273 to tyrosine 2305 inclusive;
- g) the sequence of (f), wherein one or more amino acids of the terminal peptide Thr-Arg-Tyr are deleted;
- h) a sequence starting from proline 2292 to tyrosine 2332 inclusive, and epitopes of the sequences (a) trough (h) selected from the group consisting of:
- i) an epitope comprised in the fragment starting from glycine 2242 to leucine 2251 inclusive, defined by the following sequence:
- Gly Val Thr Thr Gln Gly Val Lys Ser Leu of SEQ ID NO:
- 29;
- j) an epitope comprised in the fragment starting from isoleucine 2262 to glutamine 2270 inclusive, defined by the following sequence:
- Ile Ser Ser Ser Gln Asp Gly His Gln of SEQ ID NO:
- 30;
- k) an epitope comprised in the fragment starting from leucine 2273 to serine 2289 inclusive, defined by the following sequence:
- Leu Phe Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly Asn Gln Asp Ser of SEQ ID NO:
- 31;
- l) an epitope comprised in the fragment starting from proline 2292 to tyrosine 2305 inclusive, defined by the following sequence:
- Pro Val Val Asn Ser Leu Asp Pro Pro Leu Leu Thr Arg Tyr of SEQ ID NO:
- 32;
- m) the epitope of (1), wherein one or more amino acids of the terminal tripeptide Thr-Arg-Tyr are deleted;
- n) an epitope comprised in the fragment starting from glutamic acid 2322 to tyrosine 2332 inclusive, defined by the following sequence:
- Glu Val Leu Gly Cys Glu Ala Gln Asp Leu Tyr of SEQ ID NO:
- 33;
- and
- o) any of the preceding epitopes or sequences (a) through (n), wherein at least one amino acid has been deleted.
Dependencies are inferred from the claim text.